Scarica l'app Stockscreener
27.53
0.18%
0.05
Precedente Chiudi:
$27.48
Aprire:
$27.5
Volume 24 ore:
1.02M
Relative Volume:
1.25
Capitalizzazione di mercato:
$1.53B
Reddito:
$2.50M
Utile/perdita netta:
$-131.12M
Rapporto P/E:
-9.6831
EPS:
-2.8431
Flusso di cassa netto:
$-112.73M
1 W Prestazione:
+1.55%
1M Prestazione:
+15.12%
6M Prestazione:
+2.46%
1 anno Prestazione:
-3.23%
Intervallo 1D:
$26.72
$27.89
Intervallo di 1 settimana:
$25.96
$29.32
Portata 52W:
$21.95
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Nome
Maze Therapeutics Inc
Settore
Industria
Telefono
(650) 850-5070
Indirizzo
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
27.53 | 1.53B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-23 | Iniziato | Citigroup | Buy |
| 2026-03-18 | Iniziato | Truist | Buy |
| 2026-03-10 | Iniziato | Mizuho | Outperform |
| 2025-12-04 | Iniziato | Wells Fargo | Overweight |
| 2025-11-14 | Iniziato | Raymond James | Outperform |
| 2025-09-02 | Iniziato | BTIG Research | Buy |
| 2025-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Maze Therapeutics (NasdaqGM:MAZE) Stock Price - Simply Wall Street
Two trusts sold 31,908 and 2,593 shares under Maze Therapeutics (MAZE) CEO Jason V. Coloma’s trading plan. - Stock Titan
After exercising options, Harold Bernstein sold 16,141 Maze Therapeutics (MAZE) shares. - Stock Titan
An officer plans to sell 16,141 Maze Therapeutics (MAZE) shares on October 1, 2026. - Stock Titan
7,500 shares sold under a trading plan at Maze Therapeutics (MAZE) after an option exercise. - Stock Titan
An officer proposes selling 34,501 shares held by two trusts at Maze Therapeutics (Nasdaq: MAZE). - Stock Titan
Maze Therapeutics (Nasdaq:MAZE)Stock Analysis - Simply Wall Street
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - The Motley Fool
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - Yahoo Finance
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - The Globe and Mail
Maze Therapeutics at Citi summit: early data, bigger tests ahead By Investing.com - Investing.com South Africa
Maze Therapeutics at Citi summit: early data, bigger tests ahead By Investing.com - Investing.com Canada
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Australia
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com Nigeria
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com South Africa
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com India
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com Canada
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com UK
Maze Therapeutics (MAZE) Institutional Ownership 2026 - MarketBeat
Maze therapeutics president, R&D & CMO, sells $254,501 in shares - Investing.com
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Nigeria
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com India
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Canada
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com UK
Maze therapeutics president, R&D & CMO, sells $254,501 in shares - Investing.com
Maze Therapeutics (MAZE) R&D chief exits direct stake - Stock Titan
Maze Therapeutics CEO Coloma Jason V Offloads 22,638 Shares at $25.77 to $27.12 Each - Kalkine Media
Don't Ignore The Insider Selling In Maze Therapeutics - simplywall.st
Don't Ignore The Insider Selling In Maze Therapeutics - simplywall.st
MAZE News | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill
Maze Therapeutics CSBO Atul Dandekar Sells 6,434 Shares to Cover RSU Tax Withholding - Kalkine Media
Maze Therapeutics (NASDAQ: MAZE) officer lines up new stock sale after recent 10b5-1 trades - stocktitan.net
Maze Therapeutics Chief Executive Officer Sold Shares Worth Over $593K - TradingView
Maze Therapeutics (MAZE) legal chief sells stock for taxes - stocktitan.net
Insider at Maze Therapeutics (MAZE) sells shares to cover taxes - stocktitan.net
Maze Therapeutics (MAZE) CEO sells shares to cover taxes - stocktitan.net
Maze Therapeutics (MAZE) R&D chief sells shares to cover RSU taxes - stocktitan.net
Courtney Phillips Executes 11,000 Zero-Cost Options in Maze Therapeutics (NASDAQ: MAZE) on September 1, 2026 - Kalkine Media
Maze Therapeutics Officer Courtney Phillips Reports RSU Vesting and Stock Settlement - Kalkine Media
Maze Therapeutics CEO Jason V Coloma Reports RSU Vesting and Trust Share Sales in Form 4 Filing - Kalkine Media
RSU vesting gives Maze Therapeutics (MAZE) exec 12,500 shares - stocktitan.net
Maze Therapeutics (MAZE) CEO gets 50K shares, trims stake via trust sales - Stock Titan
Rule-based stock plan leads Maze Therapeutics (MAZE) exec to sell shares and log 20,000 RSUs - stocktitan.net
Maze Therapeutics (MAZE) legal chief gets 11,000 shares - stocktitan.net
Officer plans to sell up to $623K in Maze Therapeutics (MAZE) stock from vested RSUs - Stock Titan
Maze Therapeutics to Participate in Three Upcoming Investor Conferences - markets.businessinsider.com
Maze Therapeutics to Participate in Three Upcoming Investor Conferences - finance.yahoo.com
Maze Therapeutics (MAZE) executive plans new stock sale after recent trades - Stock Titan
MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences - finance.yahoo.com
Maze Therapeutics CSBO Dandekar divests $206,823 of common stock - Investing.com India
Maze Therapeutics Inc Azioni (MAZE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maze Therapeutics Inc Azioni (MAZE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Coloma Jason V | Officer |
Oct 01 '26 |
Proposed Sale |
27.05 |
34,501 |
933,252 |
0 |
| Bernstein Harold | President, R&D & CMO |
Oct 01 '26 |
Option Exercise |
10.42 |
16,141 |
168,189 |
16,141 |
| Bernstein Harold | President, R&D & CMO |
Oct 01 '26 |
Sale |
26.93 |
16,141 |
434,743 |
0 |
| HAROLD BERNSTEIN | Officer |
Oct 01 '26 |
Proposed Sale |
27.18 |
16,141 |
438,712 |
0 |
| Dandekar Atul | CSBO |
Sep 29 '26 |
Option Exercise |
10.42 |
7,500 |
78,150 |
39,816 |
| Dandekar Atul | CSBO |
Sep 29 '26 |
Sale |
27.06 |
7,500 |
202,921 |
32,316 |
| Bernstein Harold | President, R&D & CMO |
Sep 04 '26 |
Sale |
26.22 |
9,705 |
254,502 |
0 |
| HAROLD BERNSTEIN | Officer |
Sep 04 '26 |
Proposed Sale |
25.87 |
9,705 |
251,068 |
0 |
| Bernstein Harold | President, R&D & CMO |
Sep 03 '26 |
Sale |
26.01 |
5,189 |
134,969 |
9,705 |
| Dandekar Atul | CSBO |
Sep 03 '26 |
Sale |
26.01 |
3,243 |
84,354 |
32,316 |
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):